NEJM: Menopausal status will affect the benefit of chemotherapy-endocrine combination therapy for patients with axillary lymph node-positive breast cancer

Multi-gene prognostic analysis can accurately predict the recurrence risk of breast cancer patients with hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative, and axillary lymph node negative breast cancer .
Among them, 21-gene breast cancer detection is the most widely used
.

Recently, researchers investigated the role of recurrence risk score in predicting the benefit of adjuvant chemotherapy in patients with axillary lymph node-positive breast cancer

Breast Cancer Researchers recently investigated the role of recurrence risk scores in predicting the benefit of adjuvant chemotherapy in patients with breast cancer with positive axillary lymph nodes

In this prospective trial, the researchers recruited hormone receptor-positive, HER2-negative, and axillary lymph node-positive breast cancer patients with 1-3 positive lymph nodes.
After receiving only endocrine or combined chemotherapy (chemoendocrine therapy), the recurrence score 25 points or lower (scores from 0 to 100 points, higher scores indicate a worse prognosis)
.

The primary endpoint of the study is to determine the effect of chemotherapy on survival without invasive disease, and whether its effect is affected by the recurrence score

5083 patients participated in the grouping, of which 33.
2% were premenopausal patients, and 5018 patients were included in the study
.

In the third pre-determined interim analysis, the benefit of chemotherapy in increasing survival without invasive disease varies with menopausal status, so it is evaluated separately

For postmenopausal patients, the 5-year non-invasive disease survival rate of the endocrine therapy group was 91.

The influence of menopausal status on the prognosis of patients

The influence of menopausal status on the prognosis of patients The influence of menopausal status on the prognosis of patients

Studies believe that for premenopausal breast cancer patients with 1-3 positive axillary lymph nodes, chemical endocrine combination therapy can significantly improve the patient's non-invasive disease survival, but the benefits of chemical endocrine combination therapy for postmenopausal patients are not significant

For patients with premenopausal breast cancer with 1-3 positive axillary lymph nodes, chemical endocrine therapy can significantly improve the patient's non-invasive disease survival, but the benefit of chemical endocrine therapy for postmenopausal patients is not significant for patients with 1-3 positive For patients with premenopausal breast cancer with axillary lymph nodes, chemical endocrine therapy can significantly improve the patient's non-invasive disease survival, but the benefits of chemical endocrine therapy for postmenopausal patients are not significant

Original source:

Kevin Kalinsky et al.

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Leave a message here